Pharmacokinetics of ligustrazine ethosome patch in rats and anti-myocardial ischemia and anti-ischemic reperfusion injury effect by Liu, Xingyan et al.
© 2011 Liu et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 1391–1398
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1391
OrIgINAL reseArch
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S20263
Pharmacokinetics of ligustrazine ethosome  
patch in rats and anti-myocardial ischemia  
and anti-ischemic reperfusion injury effect
Xingyan Liu1
hong Liu1
Zhaowu Zeng2
Weihua Zhou3
Jianqiang Liu2
Zhiwei he1
1china-America cancer research 
Institute, guangdong Medical 
college, 2guangdong Key Laboratory 
for research and Development of 
Natural Drugs, guangdong Medical 
college, Dongguan, guangdong, 
3Yichun University, Yichun, Jiangxi, 
People’s republic of china
correspondence: Zhaowu Zeng 
guangdong Key Laboratory  
for research and Development  
of Natural Drugs, guangdong  
Medical college, Dongguan, guangdong, 
523808, People’s republic of china 
Tel +86 769 22896403 
Fax +86 769 22896406 
email alison0428@126.com 
 
Zhiwei he  
china-America cancer research 
Institute, guangdong Medical college, 
Dongguan, guangdong, 523808, People’s 
republic of china 
Tel +86 769 22896219 
Fax +86 769 22896406  
email zhiweihe688@yahoo.com
Abstract: The objective of this study was to investigate the pharmacokinetics of the 
  ligustrazine ethosome patch and antimyocardial ischemia and anti-ischemic reperfusion injury 
effect. Male Sprague Dawley rats were divided randomly into 3 groups: Group A (intragastric 
ligustrazine), Group B (transdermal ligustrazine ethosome patch), and Group C (conventional 
transdermal ligustrazine patch). After treatment, samples of blood and of various tissues such as 
heart, liver, spleen, lung, kidney, brain, and muscle samples were taken at different time points. 
Drug concentration was measured with HPLC, and the drug concentration–time curve was 
plotted. Pharmacokinetic software 3p97 was applied to calculate pharmacokinetic parameters 
and the area under the drug concentration–time curve (AUC) in various tissues. The rat model 
of acute myocardial ischemia was constructed with intravenous injection of pituitrin and the 
model of myocardial ischemia-perfusion injury was constructed by tying off the left anterior 
descending coronary artery of rats to observe the effect of ligustrazine ethosome patches on 
ischemic myocardium and ischemia-reperfusion injury. Results showed that AUC was highest 
in the transdermal drug delivery group of ligustrazine ethosome patch. There were significant 
differences in whole blood viscosity, plasma viscosity, hematocrit, red blood cell aggregation 
index, and deformation index between ligustrazine the ethosome patch group and ischemic 
control group (P , 0.01). Moreover, ligustrazine ethosome patches could reduce the scope of 
myocardial infarction induced by long-term ischemia. Ligustrazine ethosome patches have a 
sustained-release property. They can maintain stable and sustained blood drug concentration, 
increase bioavailability, and reduce administration times. The drug patch can decrease hemor-
heological indices of myocardial ischemia in rats, as well as protect acute ischemic myocardium 
and ischemia-reperfusion injured myocardium.
Keywords: ligustrazine, ethosome, patch, pharmacokinetics, myocardial ischemia, 
  ischemia-reperfusion injury
Introduction
Ligustrazine (4-methyl-pyrazine [tetramethylpyrazine]) is a traditional Chinese 
medicine for angina pectoris. Ligustrazine plays a role in expanding blood vessels, 
increasing coronary and cerebral blood flow, preventing platelet aggregation,   inhibiting 
thrombosis, and improving the microcirculation.1
Ligustrazine can be absorbed rapidly through the gastric wall with a quite short 
plasma elimination half-life. However, it has a long retention time in blood-rich   tissue, 
especially the liver. It also experiences enterohepatic circulation and is partially reabsorbed 
into the liver after excretion into the intestinal tract. Repeated   circulation increases the 
contact time between the drug and the intestinal tract as well as the liver. Therefore, first International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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pass effect is more evident when ligustrazine is taken orally. 
Several ligustrazine preparations via transdermal administra-
tion have been reported to improve its bioavailability and 
safety.2–5 We found that prepared ligustrazine ethosome patches 
could improve drug absorption and bioavailability.2 Ethosome 
contains a high concentration of alcohol (20%–45%) which 
promotes drug penetration through the skin, increases the accu-
mulation of the drug in the skin, and carries the drug further 
into the cells. Therefore, it has become a focus of interest for 
transdermal delivery.6,7 The process of the drug’s absorption 
from patches is more complicated than with   traditional prepara-
tions and involves multiple factors such as individual physical 
changes, cutaneous pathological changes, environment (eg, 
temperature, humidity, permeability). and effective applica-
tion area, which may affect the drug’s effects in the body. 
A study of the drug’s pharmacokinetics (PK) is necessary for 
evaluation and improvement of drug quality. In this study, the 
drug   concentration of ligustrazine ethosome was measured at 
different time points in various tissues after administration of 
patches to investigate its PK and distribution in rats. Moreover, 
studies have shown that the positive effect of ligustrazine on 
coronary tissue is mainly attributed to its pathological activities, 
such as inhibiting fibrotic myocardial ischemia-reperfusion 
injury, depressing platelet aggregation, preventing pulmonary 
hypertension,   improving blood   rheology, regulating lipid 
metabolism, increasing the activity of endogenous superoxide 
dismutase, removing oxygen free radicals, and resisting lipid 
peroxidation.8 In this experiment, the protective effects of 
ligustrazine ethosome patches on ischemic myocardium and 
ischemia-perfusion injury were observed.
Materials and instruments
High-performance  liquid  chromatography  (HPLC) 
(ZorbaxSB-C18 column, 150 mm × 4.6 mm, 5.0 µm) was 
obtained from Dionex Co (Chelmsford, MA). The Sigma 
3K30 type high-speed refrigerated centrifuge was obtained 
from Sigma Co (Munich, Germany). The Pclab system of 
collecting and processing biological signals was obtained 
from Beijing Microsignalstar Technology Development Co 
Ltd (Beijing, China). An animal respirator was obtained from 
Zhejiang University Medical Instrument Co Ltd (Zhejiang, 
China). Ligustrazine reference substance was obtained 
from the National Institute for the Control of Pharmaceuti-
cal and Biological Products (Beijing, China). Ligustrazine 
drug substance was obtained from Huapeng Natural Plant 
Development Co Ltd (Shanxi, China). The ligustrazine 
ethosome patch was self-made. Nitroderm (25 mg per 
  tablet) was obtained from Novartis Co. (Basel, Switzerland). 
  Triphenyltetrazolium chloride (TTC) was obtained from 
Sigma-Aldrich (St Louis, MO). Other reagents were of 
analytical pure grade. Male Sprague Dawley rats weighing 
250–300 g were obtained from the Experimental Animal 
Center of Xiangya School of Medicine (Hunan, China).
Methods
Preparation of rat plasma  
and tissue samples
A total of 81 normal male Sprague Dawley (SD) rats weigh-
ing 250–300 g was divided randomly into three groups: 
  intragastric administration of ligustrazine (Group A, 27 
rats), transdermal drug delivery of ligustrazine ethosome 
patch (Group B, 27 rats), and transdermal drug delivery of 
conventional ligustrazine patch (Group C, 27 rats). The doses 
were given as 100 mg  ⋅  kg–1 of net content of ligustrazine in 
all the groups. Three rats in each group were killed at 0.1, 0.2, 
0.5, 1, 2, 4, 12, and 24 hours after administration. Thereafter 
3 mL blood (with heparin) was collected from abdominal aorta, 
and then heart, liver, spleen, lung, kidney, brain, and muscle 
were taken out for refrigeration. The whole blood was centri-
fuged for 15 minutes at 4000 rpm and then the plasma was 
separated. All the samples were stored at −20°C. The plasma 
samples were handled according to Liu et al.2 A total of 0.5 g 
of tissue samples (heart, liver, spleen, lung, kidney, brain, and 
muscle) were cut into pieces and added with 1 mL of purified 
water followed by homogenate, they were then centrifuged at 
12,000 rpm. The supernatant was taken out into another tube 
and the volume adjusted to 1 mL with normal saline. Conse-
quent treatment was consistent with the plasma sample.
Measurement of ligustrazine 
concentration in various tissues  
and PK parameters
The drug concentration was measured in serum and   various 
tissue samples. The chromatographic conditions were set 
as follows: ZorbaxSB-C18 column (150 mm × 4.6 mm, 
5.0 µm), methanol/water (3:2) as mobile phase, 25°C as 
column temperature, 295 nm as detection wavelength, 
1.0 mL ⋅ min–1 as flow rate, and 20 µL as injection volume.2 
Drug concentration–time curves were plotted. PK software 
3p97 was applied to compute PK parameters and AUC, and 
plot corresponding AUC histograms.
Ligustrazine ethosome patch  
for acute ischemic myocardium
An abdominal area of 3 × 3 cm2 of 40 male SD rats was 
depilated, and samples were then divided randomly into four International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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groups of ten to construct animal models of acute myocardial 
ischemia with pituitrin (pit) given as intravenous injection.
Ligustrazine ethosome patch group: Ligustrazine etho-
some patches were applied daily to the depilated area 3 days 
prior to the experiment, followed by intraperitoneal injection 
of pit at a dose of 20 µ/kg for 30 minutes on the fourth day. 
One hour later, 0.7% of chloral hydrate was given intraperito-
neally at a dose of 7.5 mL/kg to anesthetize the rats. Next, the 
supine rats underwent thoracic surgery to expose the heart. 
A disposable syringe was inserted at the apex-beat region to 
take 5 mL of the cardiac blood for hemorheological tests.
Nitroderm transdermal therapeutic system (TTS) group: 
nitroderm TTS was applied daily on the skin 3 days before 
the experiment; the remaining procedures were consistent 
with ligustrazine ethosome patch group. Ischemic control 
group: blank ethosome patches were applied 3 days before 
the experiment and pit was injected on the fourth day with 
the same dose, method and other procedures as nitroderm 
TTS group. Blank control group: blank ethosome patch was 
applied 3 days prior to the experiment for 4 days consecutive 
and other procedures were the same as ligustrazine ethosome 
patch group except for pit injection.
Ligustrazine ethosome patch for 
myocardium ischemia-reperfusion injury
Male SD rats were divided randomly into groups D, E, and F.
Group D (single ischemia-reperfusion control group): after 
10 minutes postoperative stabilization, 2.5 mL of normal saline 
was injected followed by perfusion for 24 minutes, ischemia 
for 20 minutes, and reperfusion for 80 minutes in sequence.
Group E (ischemic preconditioning [IP] group): after 
10 minutes postoperative stabilization, 2.5 mL of normal 
saline was injected followed by ischemic precondition-
ing (repeated 3 cycles of 3 minutes ischemia followed by 
5   minutes reperfusion). Next, 20 minutes ischemia and 
80 minutes perfusion were performed.
Group F (ligustrazine ethosome patch group): ligustrazine 
ethosome patches were applied 3 days prior to the   experiment. 
After 10 minutes postoperative stabilization, 2.5 mL of nor-
mal saline was injected followed by 24 minutes perfusion, 
20   minutes ischemia, and 80 minutes reperfusion in sequence.
Ligation of coronary artery
Male SD rats were anesthetized by intraperitoneal injection 
of pentobarbital (45 mg/kg). Then rats were fixed in a supine 
position for tracheal intubation which was then connected 
with an animal breathing apparatus to control breathing at a 
respiratory rate of 55 per minute and tidal volume of 20 mL/kg. 
Left chest wall was cut to expose the heart. A thread (5–0, 
medical atraumatic suture) was passed under the left anterior 
  descending branch (LAD) between the left auricle and arte-
rial cone and two ends of the thread passed through a short 
silicone tube. Ischemia was achieved by ligaturing another 
short silicone tube and reperfusion by loosening the ligation. 
Standard limb II lead was used to record electrocardiosignals. 
The results were analyzed with Pclab Biological Signal Col-
lecting and Processing System. CT segmentation elevation 
in ECG and the appearance of cyanosis in local myocardium 
were considered to be successful ischemia and ST segmen-
tation depression and disappearance of cyanosis were taken 
as the indices of coronary artery revisualization.
IP method
Preconditioning of blocking local coronary artery and stop-
ping perfusion was applied. The process was as follows: 
ischemia was caused for 3 minutes, reperfused for 5 minutes, 
and this was repeated three times.
scoring of arrhythmia
Severity of arrhythmia was quantitatively analyzed using a 
modified arrhythmic scoring method of Curtis and Walker.9 
Its basic principles were: (1) ventricular arrhythmia . atrial 
arrhythmia; (2) for ventricular arrhythmia, ventricular fibril-
lation (VF) . ventricular tachycardia (VT) . frequent 
  ventricular premature beat . accidental ventricular prema-
ture beat; (3) the longer duration or frequency of arrhythmia, 
the higher the severity. The scores corresponding to most 
severe reperfusion arrhythmia in the heart were taken as 
arrhythmia scores (for details, see Table 1).
Measurement of scope  
of myocardial infarction
After perfusion, coronary artery LAD was ligated   permanently. 
The heart was immediately taken into normal saline. The 
residual blood in chambers of heart was cleaned. Trypan 
blue (0.8 mL) was injected retrogressively through the aorta. 
Then, the heart was stored at −20°C for 30 minutes to freeze. 
Table 1 scoring system of arrhythmia
Arrhythmia scores Arrhythmia type
0 No arrhythmia
1 Atrial arrhythmia or accidental ventricular 
premature beat
2 Frequent ventricular premature beat
3 VT (1–2/minute)
4 VT ($3/minute or VF)
Abbreviations: VF, ventricular fibrillation; VT, ventricular tachycardia.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure  2  Drug  concentration–time  curve  of  the  heart  (group  A:  intragastric 
ligustrazine;  Group  B:  transdermal  ligustrazine  ethosome  patch;  Group  C: 
conventional transdermal ligustrazine patch).
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Figure  3  Drug  concentration–time  curve  of  the  liver  (group  A:  intragastric 
ligustrazine;  Group  B:  transdermal  ligustrazine  ethosome  patch;  Group  C: 
conventional transdermal ligustrazine patch).
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Figure 1 Plasma drug concentration–time curve (Group A: intragastric ligustrazine; 
Group  B:  transdermal  ligustrazine  ethosome  patch;  Group  C:  conventional 
transdermal ligustrazine patch).
The ventricle was cut into 8–10 pieces of the same thickness 
along the direction parallel to the atrioventricular groove 
from cardiac apex to base. These slices clearly displayed 
the blue nonischemia area stained by trypan blue and area 
at risk (AAR) without blue color. These slices were placed 
into phosphate buffer with 1% TTC (37°C, pH 7.4). Normal 
myocardium contained dehydrogenase which could reduce 
colorless oxidative TTC to its red reduced form and stain 
active myocardium. Myocardial cells in the infarcted zone 
were unable to release dehydrogenase, and reduce TTC, 
because of cellular membraneous injury. As a result, the 
myocardium in infarcted zone appeared white. After immer-
sion in TTC solution for 15 minutes, heart slices clearly 
displayed red noninfarcted zone and grey infarcted zone. 
Under the anatomical lens, the blue nonischemic zone, red 
ischemia noninfarcted zone, and grey infarcted zone were 
isolated and then weighed. The percentage of myocardium 
weight of infarcted zone in myocardium weight of risk zone 
(the gross weight of red and grey myocardium) was taken 
as a measure of infarction scope.
statistical analysis
Enumeration data were compared with χ2 or Wilcoxon rank 
sum test. Measurement data were analyzed by t-test. SPSS 
software (v. 13.0; SPSS Inc, Chicago, IL) was used for 
  statistical analysis. PK data were analyzed with 3p97   software 
(Chinese Pharmacological Society, Beijing, China).
Results
Pharmacokinetics of ligustrazine 
ethosome patch in rats
Drug concentration–time curves in various tissues are shown 
in Figures 1–8. Figure 2 shows that in Groups A, B, and C, 
drug concentration in the heart decreased after administration 
for 2 hours, the smallest decrease being in Group B.
PK parameters are shown in Table 2. T1/2β was 1.94 hours 
in Group A, 18.99 hours in Group B, and 29.89 hours in Group 
C. Cmax was 67.12 µg ⋅ mL–1 in Group A, 21.05 µg ⋅ mL–1 in 
Group B, and 10.58 µg ⋅ mL–1 in Group C. As shown in 
  Figure 9, AUC of all the tissues was lower in Group A than 
in Group B. The results suggest that transdermal administra-
tion of ligustrazine ethosome patches could maintain stable 
and sustained blood drug concentration, increase bioavail-
ability, reduce application times and strengthen treatment 
efficacy. The difference between Group A and Group C was 
not significant. Table 3 shows that the peak concentration 
of ligustrazine in plasma, heart, liver, spleen, lung, brain, 
and muscle was higher in Group A than Groups B and C, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure  7  Drug  concentration–time  curve  of  the  brain  (group  A:  intragastric 
ligustrazine;  Group  B:  transdermal  ligustrazine  ethosome  patch;  Group  C: 
conventional transdermal ligustrazine patch).
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Figure  5  Drug  concentration–time  curve  of  the  lung  (group  A:  intragastric 
ligustrazine;  Group  B:  transdermal  ligustrazine  ethosome  patch;  Group  C: 
conventional transdermal ligustrazine patch).
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Figure  4  Drug  concentration–time  curve  of  the  spleen  (group  A:  intragastric 
ligustrazine;  Group  B:  transdermal  ligustrazine  ethosome  patch;  Group  C: 
conventional transdermal ligustrazine patch).
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Figure  6  Drug  concentration–time  curve  of  the  kidney  (group  A:  intragastric 
ligustrazine;  Group  B:  transdermal  ligustrazine  ethosome  patch;  Group  C: 
conventional transdermal ligustrazine patch).
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Figure  8  Drug  concentration–time  curve  of  the  muscle  (group A:  intragastric 
ligustrazine;  Group  B:  transdermal  ligustrazine  ethosome  patch;  Group  C: 
conventional transdermal ligustrazine patch).
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Figure 9 comparison of area under the drug concentration–time curve (AUc) 
in  various  tissues  of  Group  A,  B,  and  C  (Group  A:  intragastric  ligustrazine; 
Group  B:  transdermal  ligustrazine  ethosome  patch;  Group  C:  conventional 
transdermal ligustrazine patch).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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suggesting a delayed-release property in Group B and C, 
which avoided the first pass effect in the liver and degrada-
tion in the gastrointestinal tract, and reduced drug toxicity 
and adverse effects. The penetrating effect of Group B was 
significantly better compared with Group C.
Drug patches for acute ischemic 
myocardium
The changes in hemorheological indices are shown in Table 4. 
Results show that whole blood viscosity, plasma viscosity, 
hematocrit, RBC aggregation index, and RBC deformation 
index increased significantly in the ischemic control group 
compared with the blank control group (P , 0.01). There were 
statistically significant differences in whole blood viscosity, 
plasma viscosity, hematocrit, RBC aggregation index, and 
RBC deformation index between the nitroderm TTS group 
and the ischemic control group (P , 0.05). The difference of 
those parameters between the ligustrazine ethosome group and 
the ischemic control group was also significant (P , 0.01), 
showing that hemorheological indices were the highest in 
the ischemic control group. Results indicate that ligustrazine 
ethosome patch and nitroderm TTS are both efficacious in 
decreasing hemorheological indices of myocardial ischemia 
of rats, the patch group showing the highest efficacy.
Ligustrazine ethosome patch for 
myocardium ischemia-reperfusion injury
Compared with the single ischemia-reperfusion control 
group, IP prevented the occurrence of reperfusion VF, 
reduced times of ventricular premature beat during reperfu-
sion, and shortened the duration of VT (P , 0.01) (Table 5). 
The IP group showed significantly lower scores of reperfusion 
arrhythmia than the control group (P , 0.01) (Table 6). IP 
significantly decreased myocardial infarcted scope induced 
by long-term ischemia (P , 0.05) (Table 6). In comparison 
with the single ischemia-reperfusion control group, VE did 
not appear, VT times decreased (not significant P . 0.05), 
and VT duration did not shorten (not significant P . 0.05) 
(Table 5) in the ligustrazine ethosome patch group. No differ-
ences in reperfusion arrhythmia scores were noted compared 
with the control group (P . 0.05) (Table 6). Drug patches 
significantly reduced infarcted myocardium scope induced 
by long-term ischemia (P , 0.05) (Table 6).
Discussion
In this study, PK and distribution of ligustrazine ethosome 
patches given transdermally to rats were first investigated. As 
shown in Table 2, compared with orally administered ligustra-
zine, ligustrazine ethosome patches had a significantly longer 
elimination half-life and more stable plasma concentrations. 
Although the elimination half-life of conventional ligustra-
zine patches was longer than that of ligustrazine ethosome 
patches, the plasma concentration was lower. AUC represents 
a curative dose in tissues or organs of the same volume or 
weight to some extent. In Figure 9, AUC was in the sequence 
of liver . spleen . heart . brain .   kidney . lung . mus-
cle . plasma in the intragastric administration group of ligustra-
zine. AUC in the liver was up to 425.0 mg ⋅ mL–1 h–1, 5.29 times 
greater than in plasma, which suggests that ligustrazine may be 
removed primarily by bioconversion. For the transdermal drug 
delivery group of ligustrazine ethosome patch, AUC was in 
the sequence liver . heart . spleen . brain . lung . mus-
cle . kidney . plasma. For the transdermal drug delivery 
group of conventional ligustrazine patch, AUC was in the 
sequence liver . heart . spleen . brain . lung . mus-
cle . kidney . plasma. These results indicate that the drug 
is distributed mainly in the blood-rich organs such as the 
Table 3 The peak concentration of ligustrazine in various tissues (µg/mL or µg/g)
Group Plasma Heart Liver Spleen Lung Kidney Brain Muscle
A 77.6 82.1 136.0 130.7 73.2 68.9 101.8 78.1
B 52.2 43.4 66.2 62.9 39.3 32.2 49.0 37.1
c 17.6 22.1 31.5 29.1 17.4 14.1 22.1 19.0
Table 2 Pharmacokinetics parameters of three groups
Parameter Unit Values  
(Group A)
Values  
(Group B)
Values  
(Group C)
A µg ⋅ mL−1 143.62 49.96 16.69
A L/h 1.70 1.31 0.67
B µg ⋅ mL−1 0.81 5.35 1.34
β 1/h 0.05 0.04 0.02
V/F (c) mg/(µg ⋅ mL−1) 0.93 2.78 6.65
T1/2α h 0.41 0.53 1.10
T1/2β h 1.94 18.99 29.89
K21 1/h 0.06 0.22 0.08
K10 1/h 1.33 0.21 0.19
K12 1/h 0.36 0.91 0.39
Ka 1/h 6.58 3.38 3.51
Lag time 1/h 0.07 0.02 0.04
T1/2Ka h 0.11 0.20 0.20
Tpeak h 0.27 0.51 0.63
cmax µg ⋅ mL−1 67.12 21.05 10.58
AUc (µg ⋅ mL−1)*h 80.42 168.38 79.31
cL (s) mg ⋅ h−1/(µg ⋅ mL−1) 1.24 0.59 1.26International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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liver, heart, and spleen. Higher AUC in brain suggests that 
the drug can enter the central nervous system through the 
blood–brain barrier. Clinically, it has been verified to have 
a good efficacy in coronary heart disease.8 Group B showed 
2.52 times the heart AUC of Group A and 1.57 times the 
liver AUC of Group A, suggesting that ligustrazine etho-
some exerts a greater effect on the heart, but a weaker toxic 
effect on the liver. The plasma AUC of Group B was 2.09 
times that of Group A, showing that ligustrazine ethosome 
patches increase bioavailability markedly, which may be 
attributed to avoidance of oral delivery-inducing first-pass 
effect in the liver when administered transdermally and 
consequent increase of drug availability within the body. 
No significant difference existed between AUC of Groups 
A and C.
The ligustrazine level in rats depends on both penetrating 
speed and metabolic speed. When penetration speed exceeds 
metabolic speed, the drug concentration increases over time. 
Conversely, it decreases with time when metabolic speed 
exceeds penetration speed. Figure 2 shows that absorbing 
speed exceeds metabolic speed 2 hours before transdermal 
delivery and absorbing speed is less than metabolic speed 
2 hours after transdermal delivery. Ligustrazine passes 
through the skin surface, horny layer, active epidermis, and 
capillary-rich dermis in turn and finally enters the blood 
circulation.10 Figure 2 shows that animals’ organs main-
tain a high drug concentration for a relatively long period.   
The concentration in the heart was 20.4 µg ⋅ mL–1 12 hours 
after administration. Compared with oral administration, 
curative concentration was maintained at a constant release 
rate for a long time. Moreover, the relative bioavailability of 
ligustrazine ethosome was up to 209.45%, while that of a 
conventional transdermal patch was only 98.63%, as shown 
in Figure 1.
In 1960, Black established the animal model of acute 
myocardial ischemia successfully using pit,11 which was used 
widely in studies on myocardial ischemic antagonists.12,13 In 
this experiment, this model was applied to measure indices 
of whole blood viscosity, plasma viscosity, hematocrit, 
RBC aggregation index, and deformation index of rats in 
each group and clarify the differences among all the groups 
through hemorheological indices. Studies have shown that 
ligustrazine has similar pharmacological and electrophysi-
ological effects to those of calcium blockers (for example, 
see Ma et al14). It can greatly improve hemorheology and 
reduce blood fat and has excellent efficacy on blood stag-
nation of coronary heart disease.14 This study confirms that 
ligustrazine patches can protect the ischemic myocardium 
arising from coronary arterial spasm. The results indicate 
that the ischemic control group had higher hemorheological 
indices than the ligustrazine ethosome patch and nitroderm 
TTS groups. This illustrates that ligustrazine ethosome 
patch and nitroderm TTS both show efficacy in decreasing 
hemorheological indices of myocardial ischemia rats, the 
the ligustrazine ethosome patch group showing the highest 
efficacy.
Table 5 effects of ligustrazine and IP on reperfusion arrhythmia in anesthetized rats
Group n VF incidence (%) Times of ventricular premature beat VT duration (s)
control 10 20 8.09 ± 6.82 10.41 ± 5.48
IP 10 0 2.28 ± 2.23a   3.40 ± 4.66b
ethosome patch 10 0 4.05 ± 4.92 11.79 ± 8.33
Notes: compared with control group: aP , 0.05; bP , 0.01.
Abbreviations: IP, ischemic preconditioning; VF, ventricular fibrillation; VT, ventricular tachycardia.
Table 4 hemorheological indices
Item Blank control group Ischemic control group Ethosome patch group Introderm TTS group
Whole blood viscosity  
(high shear)
4.56 ± 0.96 5.94 ± 0.94a 5.19 ± 0.78c 5.58 ± 0.74b
Whole blood viscosity 
(middle shear)
5.80 ± 1.14 7.30 ± 1.21a 6.45 ± 0.95c 6.84 ± 1.00c
Whole blood viscosity  
(low shear)
9.13 ± 2.08 13.83 ± 2.73a 11.43 ± 1.90c 12.68 ± 2.44c
Plasma viscosity 0.97 ± 0.07 1.40 ± 0.10a 1.08 ± 0.05c 1.21 ± 0.08c
hematocrit 5.64 ± 1.24 8.32 ± 1.90a 7.00 ± 0.92c 7.65 ± 1.35b
RBC aggregation index 8.19 ± 1.71 12.17 ± 2.43a 9.89 ± 1.80c 11.37 ± 2.18c
RBC deformation index 0.49 ± 0.19 0.80 ± 0.12a 0.60 ± 0.14c 0.72 ± 0.16c
Notes: compared with blank control group: aP , 0.01; compared with ischemic control group: bP , 0.05; cP , 0.01.
Abbreviations: RBC, red blood cells; TTS, transdermal therapeutic system.International Journal of Nanomedicine
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Acute myocardial ischemia-reperfusion can lead to further 
injury to the ischemic myocardium, manifesting as severe 
cellular defect, intractable arrhythmia, and evident cardiac 
dysfunction in the early period of reperfusion. These are the 
critical causes of acute myocardial ischemia-reperfusion injury, 
and consequent production of free oxygen radial, intracellular 
calcium overload, energy consumption, release of norepineph-
rine, and apoptosis. IP protects myocardium by inhibiting these 
factors.11,15 In this experiment, IP reduced not only the times 
and duration of arrhythmia during reperfusion but also the 
scope of ischemic myocardial infarction. In contrast, ligustra-
zine significantly improved reperfusion arrhythmia, but greatly 
reduced the scope of myocardial infarction due to long-term 
ischemia, illustrating that this patch also has some protection 
effect on the myocardium injured by ischemia-reperfusion.
Conclusion
The ligustrazine ethosome patch can maintain stable and 
sustained blood drug concentration, increase bioavailability, 
and reduce administration times. Whole blood viscosity, 
plasma viscosity, hematocrit, RBC aggregation index, and 
deformation index differed significantly between the ligus-
trazine the ethosome patch and ischemic control groups. 
Ligustrazine ethosome patches can reduce the scope of 
myocardial infarction induced by long-term ischemia and 
have a sustained release property. They can also decrease 
hemorheological   indices of myocardial ischemia in rats, and 
protect acute ischemic   myocardium and ischemia-reperfusion 
injured myocardium.
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myocardial infarction scope in anesthetized rats
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patch group
Arrhythmia scores   3.22 ± 0.54 2.05 ± 0.92b   3.15 ± 0.67
Myocardium weight  
in infracted  
area/AAr (%)
15.33 ± 7.16 6.20 ± 7.76a 10.44 ± 7.80a
Notes: compared with control group: aP , 0.05; bP , 0.01.
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